Antiviral Drugs



Antiviral Drugs


Objectives


When you reach the end of this chapter, you will be able to do the following:



Discuss the effects of the immune system with attention to the various types of immunity.


Describe the effects of viruses in the human body.


List specific drugs categorized as non–human immunodeficiency virus (HIV) antivirals and HIV antivirals or antiretrovirals.


Discuss the process of immunosuppression in patients with viral infections, specifically those with HIV infection.


Describe the stages of acquired immunodeficiency syndrome (AIDS) and various drugs used to manage the illness.


Discuss the mechanism of action, indications, contraindications, cautions, routes, adverse effects, and toxic effects of the various non-HIV antiviral and HIV antiviral drugs.


Develop a nursing care plan that includes all phases of the nursing process for patients receiving non-HIV and HIV antiviral drugs.


Drug Profiles



Key Terms


Acquired immunodeficiency syndrome (AIDS) Infection caused by the human immunodeficiency virus (HIV), which weakens the host’s immune system, giving rise to opportunistic infections. (p. 652)


Antibodies Immunoglobulin molecules that have an antigen-specific amino acid sequence and are produced by the humoral immune system (antibodies produced from B lymphocytes) in response to exposure to a specific antigen, the purpose of which is to attack and destroy molecules of this antigen. (p. 652)


Antigen A substance, usually a protein, that is foreign to a host and causes the formation of an antibody that reacts specifically with that antibody. Examples of antigens include bacterial exotoxins, viruses, and allergens. An allergen (e.g., dust, pollen, mold) is a specific type of antigen that causes allergic reactions (see Chapter 36). (p. 652)


Antiretroviral drugs A specific term for antiviral drugs that work against retroviruses such as HIV. (p. 654)


Antiviral drugs A general term for drugs that destroy viruses, either directly or indirectly by suppressing their replication. (p. 653)


Cell-mediated immunity One of two major parts of the immune system. It consists of nonspecific immune responses mediated primarily by T lymphocytes (T cells) and other immune system cells (e.g., monocytes, macrophages, neutrophils) but not by antibody-producing cells (B lymphocytes). (p. 652)


Deoxyribonucleic acid (DNA) A nucleic acid composed of nucleotide units that contain molecules of the sugar deoxyribose, phosphate groups, and purine and pyrimidine bases. DNA molecules transmit genetic information and are found primarily in the nuclei of cells. (Compare with ribonucleic acid [RNA].) (p. 651)


Fusion The process by which viruses attach themselves to, or fuse with, the cell membranes of host cells, in preparation for infecting the cell for purposes of viral replication. (p. 651)


Genome The complete set of genetic material of any organism; it may consist of multiple chromosomes (groups of DNA or RNA molecules) in higher organisms; a single chromosome, as in bacteria; or one or two DNA or RNA molecules, as in viruses. (p. 651)


Herpesviruses Several different types of viruses belonging to the family Herpesviridae that cause various forms of herpes infection. (p. 653)


Host Any organism that is infected with a microorganism, such as bacteria or viruses. (p. 651)


Human immunodeficiency virus (HIV) The retrovirus that causes AIDS. (p. 652)


Humoral immunity One of two major parts of the immune system. It consists of specific immune responses in the form of antigen-specific antibodies produced from B lymphocytes. (p. 653)


Immunoglobulins Synonymous with immune globulins. Glycoproteins produced and used by the humoral immune system to attack and kill any substance (antigen) that is foreign to the body. An immunoglobulin with an antigen-specific amino acid sequence is called an antibody and is able to recognize and inactivate molecules of a specific antigen. (p. 653)


Influenza viruses The viruses that cause influenza, an acute viral infection of the respiratory tract. There are three types of influenza virus: A, B, and C. Currently, medications are available only to treat types A and B. (p. 653)


Nucleic acids A general term referring to DNA and RNA. These complex biomolecules contain the genetic material of all living organisms, which is passed to future generations during reproduction. (p. 652)


Nucleoside A structural component of nucleic acid molecules (DNA or RNA) that consists of a purine or pyrimidine base attached to a sugar molecule. (p. 654)


Nucleotide A nucleoside that is attached to a phosphate unit, which makes up the side chain “backbone” of a DNA or an RNA molecule. (p. 654)


Opportunistic infections Infections caused by any type of microorganism that occur in an immunocompromised host but normally would not occur in an immunocompetent host. (p. 653)


Protease An enzyme that breaks down the amino acid structure of protein molecules by chemically cleaving the peptide bonds that link together the individual amino acids. (p. 659)


Replication Any process of duplication or reproduction, such as that involved in the duplication of nucleic acid molecules (DNA or RNA) during the reproduction processes of all living organisms. This is also the term used most often to describe the entire process of viral reproduction, which occurs only inside the cells of an infected host organism. (p. 652)


Retroviruses Viruses belonging to the family Retroviridae. These viruses contain RNA (as opposed to DNA) as their genome and replicate using the enzyme reverse transcriptase. Currently the most clinically significant retrovirus is HIV. (p. 653)


Reverse transcriptase An RNA-directed DNA polymerase enzyme. It promotes the synthesis of a DNA molecule from an RNA molecule, which is the reverse of the usual process. HIV replicates in this manner. (p. 659)


Ribonucleic acid (RNA) A nucleic acid composed of nucleotide units that contain molecules of the sugar ribose, phosphate groups, and purine and pyrimidine bases. RNA molecules transmit genetic information and are found in both the nuclei and cytoplasm of cells. (Compare with deoxyribonucleic acid [DNA].) (p. 651)


Virion A mature virus particle. (p. 651)


Viruses The smallest known class of microorganisms; viruses can only replicate inside host cells. (p. 651)


image


http://evolve.elsevier.com/Lilley



Anatomy, Physiology, and Pathophysiology Overview


General Principles of Virology


Viruses are very small microorganisms, usually many times smaller than bacteria. Unlike bacteria, viruses can replicate only inside the cells of their host. In this respect, all viruses are obligate intracellular parasites. It must be emphasized that viruses are not cells, per se, but instead are particles that infect and replicate inside of cells. A mature virus particle is known as a virion. Compared with other organisms, virions have a relatively simple structure that consists of the genome, the capsid, and the envelope. The genome is the inner core of the virion, which is composed of single- or double-stranded deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) molecules, but not both.


Viruses are the simplest of all organisms. The cells of more complex organisms have much larger nucleic acid strands or multiple strands, which make up chromosomes. The viral capsid is a protein coat that surrounds and protects the genome. It also plays a role in the process of fusion between the virions and the host cells. Fusion occurs when virions attach themselves to host cells in preparation for infecting the cells. The envelope is the outermost layer of the virion and is present in some, but not all, viruses. It has a lipoprotein structure containing viral antigens that are often chemically specific for various proteins on the surface of the host cell membranes. This biochemical specificity, when present, also facilitates the fusion process. The human immunodeficiency virus (HIV), which causes acquired immune deficiency syndrome (AIDS), functions in this manner.


Viruses can enter the body through at least four routes: inhalation through the respiratory tract, ingestion via the gastrointestinal (GI) tract, transplacentally via mother to infant, and inoculation via skin or mucous membranes. The inoculation route can take several forms, including sexual contact, blood transfusions, sharing of syringes or needles, organ transplantation, and bites (including human, animal, insect, spider, and others). Once inside the body, the virus particles, or virions, begin to attach themselves to the outer membranes of host cells (cell membranes or plasma membranes) as illustrated in Figure 40-1.



The viral genome then passes through the plasma membrane into the cytoplasm of the host cell. It later enters the cell nucleus, where the replication process begins. The virion may use its own or host enzymes (or both) to direct the replication process. In the host cell nucleus, the viral genome uses the cell’s genetic material (the nucleic acids RNA and DNA) to synthesize viral nucleic acids and proteins. These are then used to construct complete new virions. These new virions then exit the infected host cell by budding through the plasma membrane and go on to infect other host cells, where the replication process continues. The changes in the cell associated with viral replication are known as the cytopathic effect and usually result in the destruction of the host cell. Repeated over time, host cell destruction gives rise to the pathologic effects of the virus, which can eventually impair or even kill the host organism.


Although this cytopathic effect is the most common outcome, there are other possible outcomes of viral infection. One is viral transformation, which involves mutation of the host cell DNA or RNA and can result in malignant (cancerous) host cells. Viruses that can induce cancer in this way are known as oncogenic viruses. More common is latent, or dormant, infection in which the virions remain inside host cells but do not actively replicate to any significant degree. For example, HIV infection may have a lengthy dormant phase of 10 years or longer before giving rise to AIDS in an infected person. HIV infection is discussed in greater detail later in the chapter in the section on retroviruses.


Viruses are ubiquitous (widespread) in the environment, and most viral infections may not even be noticed before they are eliminated by the host’s immune system. These are referred to as “silent” viral infections. Although the host’s immune system acts to neutralize viral infection, it can become overwhelmed, depending on how virulent the virus is and how rapidly it replicates inside host cells. In most cases, however, a person’s immune system is able to arrest and eliminate the virus. Host immune responses to viral infections are classified as either nonspecific or specific. Nonspecific immune responses include phagocytosis (eating) of viral particles by leukocytes such as neutrophils, macrophages, monocytes, and T lymphocytes (T cells). Another nonspecific immune response is the release of cytokines from these leukocytes. Cytokines are biochemical substances (e.g., histamine, tumor necrosis factor) that stimulate other protective immune functions. In addition, these activated immune system cells may also phagocytize infected host cells to curb the growth and spread of infection. These types of immune responses are collectively referred to as cell-mediated immunity. Cell-mediated immunity is nonspecific in the sense that it does not involve antibodies that are specific for a given antigen. In contrast, specific immune responses include the production of antibodies from B lymphocytes (B cells). These are immune-system proteins (immunoglobulins) that are chemically specific for viral antigens. This type of immune response is also called humoral immunity. Immune system function is discussed in more detail in Chapters 48 and 49.


Overview of Viral Illnesses and their Treatment


There are at least 6 classes of DNA viruses and at least 14 classes of RNA viruses that are known to infect humans. Some of the more prominent viral illnesses include smallpox (poxviruses), sore throat and conjunctivitis (adenoviruses), warts (papovaviruses), influenza (orthomyxoviruses), respiratory infections (coronaviruses, rhinoviruses), gastroenteritis (rotaviruses, Norwalk-like viruses), HIV/AIDS (retroviruses), herpes (herpesviruses), and hepatitis (hepadnaviruses). Effective drug therapy is currently available only for a relatively small number of active viral infections. The drug therapy for hepatitis is discussed further in Chapter 47. HIV belongs to the relatively unique viral class known as retroviruses and is discussed in more detail in a separate section of this chapter.


Fortunately, many viral illnesses are survivable (e.g., chickenpox), albeit bothersome and uncomfortable. The incidence of some of these illnesses has been reduced by the development of effective vaccines (e.g., vaccines for polio, smallpox, measles, chickenpox). Vaccines are discussed in more detail in Chapter 49. However, many other viral illnesses are either fatal or have much more severe long-term outcomes (e.g., hepatitis, HIV infection).


Antiviral drugs are chemicals that kill or suppress viruses by either destroying virions or inhibiting their ability to replicate. Even the best medications currently available never fully eradicate a virus completely from its host. However, the body’s immune system has a better chance of controlling or eliminating a viral infection when the ability of the virus to replicate itself is suppressed. Drugs that actually destroy virions include various disinfectants and immunoglobulins. Disinfectants such as povidone-iodine (Betadine) are virucides and are commonly used to disinfect medical equipment. Such drugs are discussed further in Chapter 38.


Immunoglobulins are concentrated antibodies that can attack and destroy viruses. They are isolated and pooled from human or animal blood. Their activity may be either nonspecific (e.g., human gamma globulin) or specific (e.g., rabies immunoglobulin, varicella-zoster immunoglobulin). Although such substances can technically be considered as antiviral drugs, they are more commonly thought of as immunizing drugs and are therefore discussed in more detail in Chapter 49. A few antiviral drugs, such as the interferons, stimulate the body’s immune system to kill the virions directly. These drugs are discussed in Chapter 47.


The current antiviral drugs are all synthetic compounds that work indirectly by inhibiting viral replication as opposed to directly by destroying mature virions themselves. Only relatively few of the known viruses can be controlled by current drug therapy. Some of the viruses in this group are the following:



Active viral infections are usually more difficult to eradicate than those caused by bacteria. One reason is that viruses replicate only inside host cells rather than replicating independently in the bloodstream or in other tissues. Most antiviral drugs must therefore enter these cells to disrupt viral replication. The need to develop antiviral drugs that are not overly toxic to host cells is one reason that there are relatively few effective antiviral medications on the market. However, the HIV/AIDS epidemic that began in the early 1980s strongly boosted antiviral drug research. This has increased the number of available antiviral drugs to treat HIV and other viral infections such as influenza, CMV infection, and varicella-zoster virus (VZV) infection. Many drugs for the treatment of HIV are approved by the U.S. Food and Drug Administration (FDA) via an accelerated process, which means that they are approved faster than other drugs, because of the nature of the illness. Because of the rapid addition of HIV drugs to the market, it is beyond the scope of this book to list every available drug. The reader is referred to the FDA website on approved AIDS drugs at www.fda.gov/ForConsumers/byAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm118915.html for the most recently approved AIDS drugs.


Another reason viral illnesses are difficult to treat is that the virus has often replicated itself many thousands or even millions of times before symptoms of illness appear. Therefore, one goal in the field of infectious disease is to be able to diagnose viral illnesses before an infecting virus has undergone widespread replication in a human host. This would theoretically allow the dual benefit of both early drug therapy and easier elimination of the virus by the host’s immune system. This has happened to some degree with HIV infection, with relatively early diagnosis made possible by blood tests to screen for HIV antibodies. Of course, the patient must also be alerted of the need to seek medical care before serious illness develops.


Recall that for a virus to replicate, virions must first attach themselves to host cell membranes in a process known as fusion. Once inside the cell, the viral genome makes nucleic acids and proteins, which are then used to build new viral particles, or virions (see Figure 40-1). All virions contain a genome that consists of either DNA or RNA, but not both. Antiviral drugs inhibit this replication process in various ways. Most antiviral drugs enter the same cells that the viruses enter. Once inside, these antiviral drugs interfere with viral nucleic acid synthesis. Other antiviral drugs work by preventing the fusion process itself.


The best responses to antiviral drug therapy are usually seen in patients with competent immune systems. The immune system can work synergistically with the drug to eliminate or suppress viral activity. Patients who are immunocompromised (have weakened immune systems) are at greater risk for opportunistic infections, which are infections caused by organisms that would not normally harm an immunocompetent person. The most common examples of immunocompromised patients are cancer patients, organ transplant recipients, and patients with AIDS. These patients are prone to frequent and often severe opportunistic infections of many types, including those caused by other (non-HIV) viruses, bacteria, fungi, and protozoans. Such infections often require long-term prophylactic antiinfective drug therapy to control the infection and prevent its recurrence because of compromised host immune functions.


Recall that there are two types of nucleic acid found in living organisms: DNA and RNA. There are also five organic bases that are the structural components of these nucleic acids. DNA consists of long chains of deoxyribose sugar molecules, phosphate groups, and purine (adenine or guanine) and pyrimidine (cytosine or thymine) bases. RNA consists of long chains of ribose sugar molecules linked to phosphate groups, together with purine (adenine or guanine) and pyrimidine (cytosine or uracil) bases. A nucleoside is a single unit consisting of a base and its attached sugar molecule. Nucleosides have names similar to their bases with minor spelling modifications (e.g., adenosine, guanosine, cytidine, thymidine). A nucleotide is a nucleoside plus its attached phosphate molecule. Most antiviral drugs are synthetic purine or pyrimidine nucleoside or nucleotide analogues. Some pharmacology texts categorize the antiviral drugs based on their nucleoside-nucleotide activity. However, for ease of learning, this book divides antiviral drugs into drugs that treat HIV infections and those that treat non-HIV viral infections. Antiretroviral drugs are indicated specifically for the treatment of infections caused by HIV, the virus that causes AIDS. The effectiveness of antiviral drugs varies widely among patients and even over time in the same patient.


Herpes Simplex Virus and Varicella-Zoster Virus Infections


The family of viruses known as Herpesviridae includes those viruses that cause all kinds of herpes infection. There are several specific types of such viruses. Herpes simplex virus type 1 (HSV-1) causes mucocutaneous herpes—usually in the form of perioral blisters (“fever blisters” or “cold sores”). Herpes simplex virus type 2 (HSV-2) causes genital herpes. Human herpesvirus 3 (HHV-3) causes both chickenpox and shingles. This virus is more commonly known as herpes zoster virus or varicella-zoster virus (VZV). Human herpesvirus 4 (HHV-4), more frequently known as Epstein-Barr virus, is associated with illnesses such as infectious mononucleosis (“mono”) and chronic fatigue syndrome. Human herpesvirus 5 (HHV-5) is more commonly known as cytomegalovirus (CMV) and is the cause of CMV retinitis (a serious viral infection of the eye) and CMV disease, which is most commonly seen in immunocompromised patients. Human herpesviruses 6 and 7 are not especially clinically significant, and infection with these viruses may be more likely to occur in immunocompromised patients. Human herpesvirus 8, also known as Kaposi’s sarcoma herpesvirus, is an oncogenic (cancer-inducing) virus believed to cause Kaposi’s sarcoma, an AIDS-associated cancer. All of these viruses occur, often asymptomatically, in varying percentages of the population. Types 3 through 7 normally do not cause diseases that require medication, except in the case of immunocompromised patients. However, the HSVs (types 1 and 2) and VZV (HHV-3) commonly cause illnesses that are now routinely treated with prescription medications.


Herpes Simplex Viruses


Although there can be anatomic overlap between the two types of herpesviruses, HSV-1 infection is most commonly associated with perioral blisters and is therefore often thought of as oral herpes. In contrast, HSV-2 infection is most commonly associated with blisters on both male and female genitalia and is therefore commonly referred to as genital herpes. Although they usually do not cause serious or life-threatening illness, both infections are annoying and highly transmissible through close physical contact (e.g., kissing, sexual intercourse). Outbreaks of painful skin lesions occur intermittently, with periods of latency (no sores or other symptoms) occurring between acute outbreaks. Although antiviral medications are not always required and are not curative, they can speed up the process of remission and reduce the duration of painful symptoms. This is especially true if the medications are started early in a given outbreak. Patients may be prescribed an ongoing lower dose of antiviral drug for prophylaxis of outbreaks. HSV infections can become serious, even life-threatening, when the patient is immunocompromised or a newborn infant. Neonatal herpes is often a life-threatening infection, and babies with this disease are often treated in neonatal intensive care units with intravenous antiviral drugs. However, treatments may fail, causing infant death and/or permanent disability. Therefore, the best strategy is to prevent transmission to the newborn infant. For this reason, obstetricians will usually recommend delivery by cesarean section (“C-section”) for any mother with active genital herpes lesions.


Varicella-Zoster Virus


Varicella-zoster virus (VZV) is a type of herpesvirus (HHV-3) that most commonly causes chickenpox (varicella) in childhood, remains dormant for many years, and can then reemerge in later adulthood as painful herpes zoster lesions known as shingles.


Chickenpox is usually an uncomfortable but self-limiting disease of childhood. However, it is highly contagious and easily spread by either direct contact with weeping lesions or via droplet inhalation. It may also lead to significant scarring. The serious condition known as Reye’s syndrome (fatty liver damage with encephalopathy) may also complicate varicella, as can other viral infections such as influenza. Herpes zoster, more commonly known as shingles, is caused by the reactivation of VZV from its dormant state, often decades after a case of childhood chickenpox. It is also referred to simply as zoster. Its most common manifestation is in the form of skin lesions that follow nerve tracts, known as dermatomes, along the skin surface. The most common site of these lesions is around the side of the trunk, although they can appear in other areas (e.g., along trigeminal nerve dermatomes of the face). Zoster lesions are often quite painful, and some patients even require opioids for pain control. In addition, postherpetic neuralgias (long-term nerve pain) remain following shingles outbreaks in up to 50% of elderly patients. Early administration of antiviral drugs such as acyclovir may speed recovery, but this effect is usually not dramatic. The best results are generally seen when the antiviral drug is started within 72 hours of symptom onset.


Active childhood varicella (chickenpox) infections are usually self-limiting and are not normally treated with antiviral drugs, except in high-risk (e.g., immunocompromised) pediatric patients. The varicella virus vaccine was approved in 1995 and is now routinely recommended for healthy children older than 1 year of age who have not had chickenpox. A new vaccine, Zostavax, is available for prevention of herpes shingles in patients 50 years of age or older (see Chapter 49).


In a small percentage of shingles cases, skin lesions may progress beyond the usual dermatome regions, and the virus can cause solid organ infections such as pneumonitis, hepatitis, encephalitis, and optic neuritis (infection of the optic nerve). Such infections are uncommon, with elderly and immunocompromised patients being the most vulnerable. Rarely, these serious infections can be caused by first-time exposure to varicella (chickenpox). In general, these more serious infections require intravenous antiviral drugs, especially in high-risk patients. Intravenous acyclovir is the most commonly used drug, and it may prevent fatalities or disability. Less serious infections are usually treated orally with acyclovir, valacyclovir, or famciclovir. Topical dosage forms of some of these drugs are also available and are discussed further in Chapter 56. Although VZV reactivation is comparable in pathology to that of HSV (e.g., oral or genital herpes lesions), VZV reactivation occurs much less regularly than does HSV reactivation because of a lack of reactivation genes. Secondary bacterial infections (e.g., group A Streptococcus skin infection) are common with VZV exacerbations, so antibiotics may also be needed. This is especially true in cases of ophthalmic involvement.


Pharmacology Overview


Antivirals (Non-HIV)


The drugs discussed in this section include those used to treat non-HIV viral infections such as those caused by influenza viruses, HSV, VZV, and CMV. There are also antiviral drugs used to treat infections with hepatitis A, B, and C viruses. However, hepatitis treatment is covered in detail in Chapter 47 because it involves some additional unique drug therapy.


Mechanism of Action and Drug Effects


Most of the current antiviral drugs work by blocking the activity of a polymerase enzyme that normally stimulates the synthesis of new viral genomes. The result is impaired viral replication, which results in viral concentrations low enough to allow elimination of the virus by the patient’s immune system. If this does not occur, the virus may either enter a dormant state or remain at a low level of replication with continuous drug therapy.


Indications


The antivirals discussed in this section are those used to treat HSV, VZV, and CMV infections and are listed in Table 40-1.



Contraindications


Most of the antiviral drugs used to treat non-HIV viral infections are surprisingly well tolerated. The only usual contraindication for most of these drugs is known severe drug allergy. However, a small number of contraindications are listed for a few of the antiviral drugs. Amantadine is contraindicated in lactating women, children younger than 12 months of age, and patients with an eczematous rash. Famciclovir is contraindicated in cases of allergy to the drug itself or to a similar drug called penciclovir, which is used topically to treat herpes labialis (perioral sores). Cidofovir has a strong propensity for renal toxicity, and it is contraindicated in patients who already have severely compromised renal function as well as those receiving concurrent drug therapy with other highly nephrotoxic drugs. It is also contraindicated in cases of allergy to probenecid, because probenecid is recommended as concurrent drug therapy with cidofovir to help alleviate its nephrotoxicity. Ribavirin also has additional specific contraindications besides drug allergy. Because of the drug’s teratogenic potential, it is also contraindicated in pregnant women and even in their male sexual partners. The aerosol form must not be used by pregnant women or by women who may become pregnant during exposure to the drug. This includes health care providers administering the drug in aerosol form, because of the potential for second-hand inhalation on the part of the health care provider.


Adverse Effects


The adverse effects of the antiviral drugs are as different as the drugs themselves. Each has its own specific adverse effect profile. Because viruses reproduce in human cells, selective killing is difficult, and consequently many healthy human cells, in addition to virally infected cells, may be killed in the process, which results in more serious toxicities for these drugs. However, this effect is usually not as pronounced as in cancer chemotherapy, which often kills many more healthy cells. The more serious adverse effects are listed by drug in Table 40-2.



Interactions


Significant drug interactions that occur with the antiviral drugs arise most often when they are administered via systemic routes such as intravenously and orally. Many of these drugs are also applied topically to the eye or body, however, and the incidence of drug interactions associated with these routes of administration is much lower. Selected common drug interactions for both antiviral and antiretroviral drugs are listed in Table 40-3.



TABLE 40-3


SELECTED ANTIVIRAL DRUGS: INTERACTIONS





























































































































DRUG INTERACTING DRUGS INTERACTION
Non-HIV Drugs
acyclovir interferon Additive antiviral effects
  probenecid Increased acyclovir levels due to decreasing renal clearance
  zidovudine Increased risk for neurotoxicity
amantadine Anticholinergic drugs Increased adverse anticholinergic effects
  CNS stimulants Additive CNS stimulant effects
ganciclovir foscarnet Additive or synergistic effect against CMV and HSV type 2
  imipenem Increased risk for seizures
  zidovudine Increased risk for hematologic toxicity (i.e., bone marrow suppression)
ribavirin Nucleoside reverse transcriptase inhibitors Increased risk for hepatotoxicity and lactic acidosis
HIV Drugs
indinavir Drugs metabolized by the CYP3A4 hepatic microsomal enzyme system (azole antifungals, clarithromycin, doxycycline, erythromycin, isoniazid, nefazodone, nicardipine, protease inhibitors, quinidine, statins, telithromycin, and verapamil) Competition for metabolism resulting in elevated blood levels and potential toxicity
  rifabutin and ketoconazole Increased plasma concentrations of rifabutin and ketoconazole
  rifampin Increased metabolism of indinavir
nevirapine Drugs metabolized by the CYP3A4 hepatic microsomal enzyme system (see indinavir) Increased metabolism of these drugs
  Oral contraceptives Decreased plasma concentrations of oral contraceptives
  Protease inhibitors Decreased plasma concentrations of protease inhibitors
  rifampin and rifabutin Decreased nevirapine serum concentration
tenofovir acyclovir, cidofovir, ganciclovir, valacyclovir May increase serum concentrations of tenofovir
  Protease inhibitors Increased serum concentrations of tenofovir
maraviroc CYP3A4 inhibitors (see indinavir) May increase maraviroc toxicity
  CYP3A4 inducers (phenytoin, carbamazepine, rifampin) May decrease effects of maraviroc
  St. John’s wort May decrease effects of maraviroc
raltegravir atazanavir (with or without ritonavir) May increase effects of raltegravir
  rifampin May decrease effects of raltegravir
zidovudine acyclovir Increased neurotoxicity
  interferon beta Increased serum levels of zidovudine
  Cytotoxic drugs Increased risk for hematologic toxicity
  didanosine and zalcitabine Additive or synergistic effect against HIV
  ganciclovir and ribavirin Antagonize the antiviral action of zidovudine


Image


CMV, Cytomegalovirus; CNS, central nervous system; CYP3A4, cytochrome P-450 enzyme 3A4; HIV, human immunodeficiency virus.


Dosages


For dosage information on some of the commonly used antiviral drugs, see the table on this page.


Drug Profiles


amantadine and rimantadine


Amantadine (Symmetrel), one of the earliest antiviral drugs, has a narrow antiviral spectrum in that it is active only against influenza A viruses. It has been used both prophylactically and therapeutically. However, the most recent guidelines of the Centers for Disease Control and Prevention (CDC) do not recommend the use of amantadine or rimantadine to prevent or



DOSAGES
Antiviral Drugs (Non-HIV)







































DRUG (PREGNANCY CATEGORY) PHARMACOLOGIC CLASS USUAL DOSAGE RANGE INDICATIONS
♦ acyclovir (Zovirax) (B) Antiherpesvirus
HSV-1 and HSV-2 infection, including genital herpes, mucocutaneous herpes, herpes encephalitis; herpes zoster (shingles); higher-dose therapy for acute episodes; lower-dose therapy for viral suppression
    PO: 20 mg/kg (max 800 mg/dose) 5 times daily × 5 days Chickenpox (varicella)
amantadine (Symmetrel) (C) Antiinfluenza
Influenza A
ganciclovir (Cytovene)(C) Antiviral
CMV retinitis treatment or maintenance
oseltamivir (Tamiflu) (C) Antiinfluenza
Influenza A or B
ribavirin (Virazole) (X) Anti-RSV

Stay updated, free articles. Join our Telegram channel

May 9, 2017 | Posted by in NURSING | Comments Off on Antiviral Drugs

Full access? Get Clinical Tree

Get Clinical Tree app for offline access